Genmab Fair Value
GE
The fair market value of GE9.DU stock is 396.9 EUR. Relative to the market price of 205.9 EUR Genmab is undervalued by 92.8%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Genmab Valuation
Current GE9.DU share ticker price is 205.9 EUR.
The fair value level of 396.9 EUR can be considered as an effective entry point for long-term investors to start investing in GE9.DU stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 93% lower its fair value
Current price is 38% lower its minimum value
Current price is 235% lower its maximum value
Market price:
GE9.DU stock is greatly undervalued
It means the current price may concern as a Low Risk Entry Point
Genmab A/S Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
61.68
2
Median P/E over 5 years
35.5
3
Minimum P/E over 5 years
25.45
4
Earning per share (last 12 months)
83.24 DKK
Maximum value
1
x
4
=
689.54 EUR
Fair value
2
x
4
=
396.9 EUR
Minimum value
3
x
4
=
284.52 EUR
Genmab A/S price metrics
1.15
Annual return (geometric mean)
31.88
Risk (standard deviation) of returns
β
0.05
Beta (volatility compared to market)